Description: Non-sedating Anti histamines compete with Histamine for H1-receptor sites on the effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. They exhibit selective histamine H1 receptor antagonistic activity.

Indication(s): Treatment of perennial allergic rhinitis  
Treatment of nasal and non-nasal seasonal allergic rhinitis  
Treatment of urticaria  
Treatment of chronic idiopathic urticaria

Reasons for Step Therapy: ❑ Cost  ❑ Potential for misuse  ❑ Toxicity

Criteria for Approval: The patient has had a 30 day trial of Claritin-OTC, Loratidine OTC, Allegra OTC, or Zyrtec OTC

Reason for Denial of Benefit: Patient does not meet above criteria.

Benefit Approval: Approval for one year

References: